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Review
French regulations stipulate that a blood type is regarded 
as rare if its prevalence is 4 in 1000 or less (i.e., ≤1 in 250) 
in the general population.1,2 The National Rare Blood Donor 
Database was implemented in France in the late 1960s to 
ensure the transfusion and obstetric safety of patients with rare 
blood phenotypes.3,4 The national rare blood bank was later set 
up in the early 1980s.5 Potential rare blood donors from the 
national database are highly encouraged to donate blood on 
a routine basis for the national rare blood bank. This facility, 
located in the city of Créteil (a few kilometers from Paris), is 
co-managed by the National Immunohematology Reference 
Laboratory (National Reference Center for Blood Groups 
[CNRGS], Department of the National Institute of Blood 
Transfusion, Paris, France) and the French National Blood 
Service (Etablissement Français du Sang, Ile de France, Ivry/
Seine, France). Confirmation of the rare blood type, registration 
of new people with a rare blood type in the national database, 
choice of red blood cell (RBC) units to be frozen, and selection 
and delivery authorization of rare blood units are exclusively 
carried out by the national Immunohematology Reference 
Laboratory (IRL). To date, 12,929 individuals (patients and 
donors) are listed in the National Registry of People with a 
Rare Blood Phenotype or Genotype.
Rare blood units from the national rare blood bank are 
frozen according to the Cohn method, using glycerol in an ionic 
medium to achieve a final glycerol concentration of 40 percent 
(wt/vol), the so-called high-glycerol method. RBC units are 
subsequently stored at a mean temperature of –80°C. Since 
late 2005, the Haemonetics Automated Cell Processor (ACP) 
215 closed-circuit instrument (Haemonetics, Braintree, MA) 
has been systematically used to glycerolize and deglycerolize 
RBC units, allowing for a 7-day shelf life for thawed units when 
stored at 2°C to 6°C in a saline-adenine-glucose-mannitol 
additive solution.6,7
The national rare blood bank currently includes 6,539 
cryopreserved blood units, from 1,744 blood donors. This 
facility maintains two categories of rare blood units: (i) 
RBCs negative for a high-prevalence antigen (prevalence 
≤1 in 250); and (ii) RBCs negative for multiple common 
antigens within the Rh system: r′r′, r″r″, ryry, and RzRz. This 
prevalence threshold is not exclusively considered for defining 
a rare blood donor in our country, however. The whole 
phenotype is taken into account in order to assess the need for 
cryopreservation of the RBC unit with the intent of ensuring 
maximal efficiency of the rare blood bank. For example, and 
as of today, a donor with a rare k– phenotype will be eligible 
for RBC unit cryopreservation only if the blood type is group 
O, R1R1 or R2R2, or rr, with three homozygous expressions for 
Fya/Fyb, Jka/Jkb, and S/s, in order to fulfill the most common 
requests for multiply-alloimmunized patients or to prevent 
alloimmunization to the major RBC antigens.
Of note, RBCs negative for multiple common antigens 
within several different blood group systems are not currently 
considered for cryopreservation at the national rare blood 
bank. This practice is explained by the fact that all donors in 
France have been typed for Rh (C, E, c, e) and K for more than 
20 years and around 20 percent of repeat blood donors are 
subject to extended phenotyping (Fya, Fyb, Jka, Jkb, M, N, S, 
and s).
Activity Report from January 2012 to  
December 2014
From 2012 to 2014, 797 rare donors gave blood, including 
214 new donors. A total of 2113 RBC units were provided. In 
the same period of time, 167 patients were transfused, for a 
total of 854 RBC units and 441 transfusion episodes. This 
corresponds to an average of 285 RBC units per year (4.3 per 
106 inhabitants per year). Of note, this value increased by 70 
percent since the early 2000s.6 Among those 167 patients, 
72 (43%) were of African/Caribbean descent, accounting for 
314 (39.4%) of the delivered RBC units. Most of the patients 
of African/Caribbean descent suffered from sickle cell 
disease (70%). As a result, 30 percent of the requested rare 
cryopreserved units were transfused to patients with sickle 
cell disease from 2012 to 2014 in France.
The top 10 most requested rare phenotypes during that 
period were as follows: Fy(a–b–) (38%), k– (15%), r′r′ (12%), 
Lu(b–) (5.4%), S–s–U– (4.1%), S–s–U+var (3.5%), r″r″ (2.3%), 
Yt(a–) (1.8%), GE:–2,3 (1.6%), and Vel– (1.6%) (Fig. 1).
In this 3-year timeframe, 44 rare RBC units (5.2%) were 
shipped abroad (Table 1): Germany 26 (59%), Switzerland 
6 (14%), Belgium 4 (9%), Sweden 3 (7%), Iceland 2 (4.5%), 
Monaco (4.5%), and United Kingdom 1 (2%).
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To our knowledge, no unfilled rare blood request was 
reported in our country from 2012 to 2014.
Transfusion of Incompatible Blood
To the best of our knowledge, seven cases of transfusion 
with incompatible blood were reported from 2012 to 2014. 
The alloantibodies involved were as follows: anti-Lub, anti-U, 
anti-Coa (2 cases), anti-Yta (2 cases), and anti-AnWj.
For the AnWj– patient (group A, E–c–, K–) with a strong 
anti-AnWj (antibody titer >2048), multiple transfusions with 
In(Lu) rare blood units were uneventfully carried out (no 
AnWj– donor available in France). A major decrease of the 
stock of ABO/Rh-compatible In(Lu) RBC units occurred. As 
we were informed that the patient was under palliative care, 
the possibility of the so-called “in vivo crossmatch” procedure 
(transfusion of 50 mL incompatible blood, with close clinical 
and biological monitoring)8,9 was collectively considered. 
A prophylactic treatment was given 8 hours prior to the 
transfusion, based on a bolus of corticosteroids (equivalent to 
100 mg of hydrocortisone) and intravenous immunoglobulin 
infusion (1 g/kg).10 A blood sample drawn after infusion of 
50 mL incompatible blood showed mild hemolysis of plasma 
and a weakly positive direct antiglobulin test. Transfusion 
with AnWj+ RBCs was decided to be cautiously carried on. 
Severe fever and rigors occurred at the end of the blood bag 
infusion, however, and the clinicians decided to immediately 
stop the transfusion. The few subsequent transfusions in this 
patient were as previously performed with In(Lu) RBCs, until 
the end of his life.
Anti-Lub was responsible for a poor hemoglobin increase 
and a moderate febrile non-hemolytic transfusion reaction. 
Fig. 1 The top 24 rare blood phenotypes requested from January 
2012 to December 2014 in France.
Table 1. International requests supported by the French national rare blood program from 2012 to 2014
Country Rare phenotype ABO/Rh/K Alloantibodies Number of RBC units provided
Belgium Yt(a–) O, D–C–E–c+e+; K– Anti-Yta, anti-Lua 2
Belgium Sec– (RNRN, RH:–46) O, E–c–; K– Anti-Sec, anti-E 2
Germany Fy(a–b–) O, D+C–E–c+e+; K– Anti-Fy3 suspected 3
Germany Fy(a–b–) O, D+C–E–c+e+; K+ Anti-Fy3, anti-C, anti-E, anti-s, anti-P1 3
Germany S–s–U– O, D+C–E–c+e+; K– Anti-U, anti-M 1
Germany S–s–U– B, D+C–E–c+e+; K– Anti-U 11
Germany r´r´ O, D–C+E–c–e+; K– Anti-D, anti-c, anti-S 8
Iceland D – – O, D+C–E–c–e–; K– Anti-Hr0 2
Monaco Fy(a–b–) A, D+C–E–c+e+; K– Anti-Fy3, anti-A1, anti-E, anti-C, 
anti-Fya, anti-Jka, anti-Lua, antibody 
to a high-prevalence antigen of 
undetermined specificity
2 autologous units for elective surgery 
(no possibility to cryopreserve RBC 
units in Monaco)
Sweden S–s–U– A, D+C–E–c+e+; K– Anti-U 2
Sweden S–s–U– A, D–C–E–c+e+; K– Anti-U, anti-D 1
Switzerland GE:–2,3 O, D+C–E+c+e+; K– Anti-Ge2 2
Switzerland P1k A, D+C+E+c+e+ Anti-P 3
Switzerland Oh (Bombay) Oh, D+C+E–c+e+; K– Anti-H 1
United Kingdom D – – O, D+C–E–c–e–; K– Anti-Hr0 1
RBC = red blood cell.
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Incompatible transfusion was uneventful for anti-Yta and 
rather unexpectedly for anti-U. The two cases of anti-Coa 
incompatibility were said to be of undetermined outcome.
Incentive Measures for Rare Blood Donors
New rare blood donors receive a specific card with mention 
of their rare phenotype and an explanatory accompanying 
letter. Their siblings are also encouraged to be tested for the 
same identified rare specificity. Those documents are sent 
to the regional medical referee of the French National Blood 
Service and are further forwarded to the donor. For the 
most exceptional blood types, the medical referee usually 
contacts the donors by phone to make them aware of the 
great importance of giving blood on a regular basis. When a 
decrease in the inventory of a given rare specificity occurs, the 
national IRL contacts the regional medical referee to ask for 
new blood donations. At the end of 2014, a season’s greetings 
card was sent to the most loyal rare blood donors.
Rhnull Donors
The French national rare donor database contains only 
one Rhnull active donor, group A (Rhnull of the so-called 
regulator type, with compound heterozygous mutations in the 
RHAG gene). This donor lives in Lausanne, Switzerland. No 
rare blood bank exists in that country. In addition, the different 
rules for blood donor testing between Switzerland and France 
(testing for anti-HTLV-I/II and anti-HBc are mandatory in 
France) makes the importation of rare blood in our country 
even more difficult. As a result, this donor, very aware of the 
rarity and usefulness of his very special blood, kindly travels 
to the French–Swiss border to donate in France.11 As of today, 
eight RBC units from this donor are cryopreserved at the 
national rare blood bank.
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